We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Annexon Inc
2 own
5 watching
Current Price
$7.06
$-0.14
(-1.94%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
336.24M
52-Week High
8.2
52-Week Low
2.06
Average Volume
0.22M
Dividend Yield
--
P/E Ratio
--
Market Capitalization336.24M52-Week High8.252-Week Low2.06Average Volume0.22MDividend Yield--P/E Ratio--What does the Annexon Inc do?
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company s C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Read More
How much money does Annexon Inc make?
News & Events about Annexon Inc.
Zolmax
19days ago
Annexon, Inc. (NASDAQ:ANNX Get Rating) Equities researchers at Jefferies Financial Group issued their FY2027 earnings per share estimates for shares of Annexon in a report released on Tuesday, January 10th. Jefferies Financial Group analyst S. Jeong forecasts that the company will post earnings of...
Globe Newswire
25days ago
Mid-stage and Pivotal Trials of ANX005, ANX007 and ANX1502 Poised to Achieve Numerous Catalysts in Multiple Disease Indications Well-Capitalized with Operating Runway into 2025 Company to Present Pipeline Updates at 41st Annual J.P. Morgan Healthcare Conferenceon January 11, 2023, at 7:30 a.m. PT ...
Globe Newswire
27days ago
BRISBANE, Calif., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that ...
Globe Newswire
6 months ago
BRISBANE, Calif., July 08, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that it ...
Ticker Report
11 months ago
Geode Capital Management LLC increased its position in shares of Annexon, Inc. (NASDAQ:ANNX Get Rating) by 4.8% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 425,043 shares of the companys stock after ...
Frequently Asked Questions
Frequently Asked Questions
What is Annexon Inc share price today?
Can Indians buy Annexon Inc shares?
How can I buy Annexon Inc shares from India?
Can Fractional shares of Annexon Inc be purchased?
What are the documents required to start investing in Annexon Inc stocks?
What is today’s traded volume of Annexon Inc?
What is today’s market capitalisation of Annexon Inc?
What is the 52-Week High and Low Range of Annexon Inc?
What percentage is Annexon Inc down from its 52-Week High?
What percentage is Annexon Inc up from its 52-Week Low?
Current Price
$7.06
$-0.14
(-1.94%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.